Merck patent on iminothiadiazine dioxide scaffold BACE inhibitors encompassing the verubecestat (MK-8931) compound class; covers C2-ring-substituted variants of the thiadiazinane core used in the EPOCH and APECS Phase 3 trials.

Evidence span

Merck patent on iminothiadiazine dioxide scaffold BACE inhibitors encompassing the verubecestat (MK-8931) compound class; covers C2-ring-substituted variants of the thiadiazinane core used in the EPOCH and APECS Phase 3 trials.

From reviewer:will-blair-bot

Method & conditions

Evidence type

observational

Method

manual state transition

Conditions

Iminothiadiazine dioxide compounds with thioamide/amidine/amide-oxime substituents as BACE1/2 inhibitors; pharmaceutical compositions; treatment and prevention of Alzheimer's disease and amyloid-related neurodegeneration. Note: verubecestat's precise composition claims may reside in a related Merck patent; ID verified as same scaffold class but exact verubecestat CoM patent number uncertain.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required